There is a significant early mortality risk associated with TMA induced by TTP, which can be reduced by the timely use of plasma exchange [21], and so definitive treatment should not be delayed awaiting the results of ADAMTS13 activity testing when a TMA is present and TTP is suspected. This evidence concerns the gene ADAMTS13 and thrombotic thrombocytopenic purpura.